- Injection (lyophilized cake) 500 mg (with approximately 780 mg of L-arginine per gram aztreonam)
- Injection (lyophilized cake) 1 g (with approximately 780 mg of L-arginine per gram aztreonam)
- Injection (lyophilized cake) 2 g (with approximately 780 mg of L-arginine per gram aztreonam)
- Powder for inhalation (lyophilized) 75 mg
Inhibits bacterial cell wall synthesis.
C max is 54 mcg/mL (500 mg dose), 90 mcg/mL (1 g dose), and 204 mcg/mL (2 g dose) immediately after administration.IM
T max is approximately 1 h; produces serum concentrations comparable with IV doses.Inhalation
C max is 0.59 mcg/mL; T max is approximately 1 h.
Vd is approximately 12.6 L; approximately 56% protein bound. Widely distributed to fluids and tissues, including CSF (inflamed meninges) and breast milk; crosses placenta.
The half-life is approximately 1.7 h (2.1 h for inhalation); serum Cl is 91 mL/min; renal Cl is 56 mL/min; 60% to 70% is recovered in the urine within 8 h; approximately 12% recovered in the feces.
Special PopulationsRenal Function Impairment
Serum half-life may be prolonged.Hepatic Function Impairment
Serum half-life may be prolonged.Elderly
Serum half-life may be prolonged.
Indications and UsageInjection
Treatment of infections of urinary tract, lower respiratory tract, and skin and skin structure; intra-abdominal infections; gynecologic infections; surgical infections; and septicemia caused by susceptible microorganisms.Inhalation
To improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa .
Treatment of acute, uncomplicated gonorrhea in patients with penicillin-resistant gonococci.
Known allergy to aztreonam.
Dosage and AdministrationUTI
IM / IV 500 mg or 1 g every 8 to 12 h.Systemic Infections
IM / IV 1 to 2 g every 6 to 12 h.Children
IM / IV 30 to 50 mg/kg every 4 to 8 h.Acute Uncomplicated Gonorrhea
IM 1 g. Max recommended dosage is 8 g/day.Cystic fibrosis
Adults and Children 7 yr of age and older
Inhalation 75 mg 3 times daily (at least 4 h apart) for 28 days.
- For inhalation use only using the Altera Nebulizer System. Do not administer with any other nebulizer.
- Use a bronchodilator before administration. Short-acting bronchodilators can be taken between 15 min and 4 h prior to each dose of aztreonam. Long-acting bronchodilators can be taken between 30 min and 12 h prior to administration of aztreonam. For patients taking multiple inhaled therapies, the recommended order of administration is as follows: bronchodilator, mucolytics, and, lastly, aztreonam.
- Refer to the manufacturer's prescribing information for preparation and administration instructions.
- Do not mix with any other drugs in the Altera Nebulizer Handset.
Shake reconstituted solutions vigorously immediately after mixing. Reconstituted solutions not exceeding 2% are stable at room temperature for 48 h; stable under refrigeration for 7 days. Discard unused solutions. See the prescribing information for further storage and incompatibility information. Frozen infusion solutions may be stored for up to 3 mo at −4°F.Inhalation
Store at 36° to 46°F; may be stored up to 77°F for up to 28 days. Do not separate the aztreonam vials from the diluent ampules. Protect from light. Do not use aztreonam if it has been stored at room temperature for more than 28 days.
Drug InteractionsAminoglyclosides (eg, gentamicin)
If an aminoglycoside is used concurrently with aztreonam, especially if high dosages of the former are used or if therapy is prolonged, monitor renal function because of potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics.Beta-lactamase–inducing antibiotics (eg, cefoxitin, imipenem)
May antagonize activity of aztreonam; do not use concurrently.
Nafcillin sodium, cephradine, and metronidazole are incompatible in admixture.
Nasal congestion (16%); pharyngolaryngeal pain (12%).
Abdominal pain (7%); vomiting (6%).Injection
Diarrhea; nausea; pseudomembranous colitis; vomiting.
Phlebitis/thrombophlebitis after IV administration; pain/swelling at IM injection site.
Cough (54%); wheezing (16%); bronchospasm (3%).Injection
Chest discomfort (8%); pyrexia (13%).Injection
Review culture and sensitivity of organism as available. Obtain baseline forced expiratory volume at 1 sec (FEV 1 ) prior to initiating inhalation therapy and as needed during therapy. Monitor patients for signs and symptoms of an allergic reaction.
Category B .
Excreted in breast milk.
Safety and efficacy in children younger than 9 mo of age not established (injection); safety and efficacy in children younger than 7 yr of age not established (inhalation).
Reactions range from mild to life-threatening. Administer cautiously to penicillin- or cephalosporin-sensitive patients because of possible cross reactivity.
Reduced dose required for aztreonam injection.
May result in overgrowth of nonsusceptible bacterial or fungal organisms.
Bronchospasm may occur with inhalation use. Patients whose FEV 1 increased during aztreonam inhalation therapy and then decreased after the treatment period were sometimes treated for pulmonary exacerbation. Consider baseline FEV 1 measured prior to aztreonam therapy and the presence of other symptoms when evaluating patients for pulmonary exacerbation.
- Encourage patient to increase fluid intake to 2,000 to 3,000 mL/day, if allowed.
- Inform patient to notify health care provider if rash or difficulty breathing is experienced.
- If therapy is discontinued because of allergic reaction, explain significance of penicillin allergy and of potential problems with cephalosporins.
- Caution patient against skipping doses or stopping treatment early, which could result in recurrence of symptoms and potential resistance of the organism to this drug.
- Advise patients that aztreonam is for inhalation use only and should only be administered using the Altera Nebulizer System.
- Instruct patients only to reconstitute aztreonam with the provided diluent and not to mix other drugs in the Altera Nebulizer Handset.
- Inform patients if they miss a dose, to take all 3 daily doses as long as the doses are at least 4 hours apart.
- Advise patients to use a bronchodilator prior to aztreonam. Advise patients taking several inhaled medications to use the medications in the following order: bronchodilator, mucolytics, and, lastly, aztreonam.
Copyright © 2009 Wolters Kluwer Health.
More Aztreonam resources
- Aztreonam Prescribing Information (FDA)
- Aztreonam Monograph (AHFS DI)
- aztreonam Inhalation Advanced Consumer (Micromedex) - Includes Dosage Information
- aztreonam MedFacts Consumer Leaflet (Wolters Kluwer)
- Azactam Advanced Consumer (Micromedex) - Includes Dosage Information
- Azactam Prescribing Information (FDA)
- Cayston Prescribing Information (FDA)
- Cayston MedFacts Consumer Leaflet (Wolters Kluwer)
- Cayston Consumer Overview